Eversheds comments on Department of Health scheme to reduce price of prescription drugs
Eversheds has commented on the UK Department of Health’s new scheme that is designed to reduce the price of prescription drugs, saying that it should be a good outcome for UK industry and the government alike.
Simon Crossley, pharmaceutical industry expert at Eversheds, said: ‘This new deal represents the end of a period of uncertainty and tough negotiation between the industry and British government as national health bodies across Europe seek to reduce the public cost of health provision amid continuing economic difficulties and austerity.
‘The new PPRS [Pharmaceutical Price Regulation Scheme] should represent a good outcome for both stakeholders with the government securing savings to the UK’s drugs bill and the pharmaceutical industry avoiding the prospect of an enforced regime had agreement not been reached.’
News from Eversheds
News from The Lawyer
Briefings from Eversheds
Rather than a single new body to take on its role, the OFT’s functions have been spread between a number of different bodies, some old and some new.
As it moves into its second year as the FCA, the FCA has recently published its Business Plan for 2014–15 and its second annual Risk Outlook.
Analysis from The Lawyer
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe